NASDAQ:BCPC Balchem (BCPC) Stock Price, News & Analysis $161.75 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$161.83 +0.08 (+0.05%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Balchem Stock (NASDAQ:BCPC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Balchem alerts:Sign Up Key Stats Today's Range$161.46▼$162.6150-Day Range$158.93▼$177.6652-Week Range$139.17▼$183.90Volume128,827 shsAverage Volume203,171 shsMarket Capitalization$5.20 billionP/E Ratio33.21Dividend Yield0.59%Price Target$176.00Consensus RatingBuy Company Overview Balchem Corporation, trading on the Nasdaq under the ticker BCPC, is a global specialty chemicals and nutrition company. The firm develops, manufactures and markets performance ingredients and ingredient systems that address a wide range of industries, including human and animal nutrition, food and beverage protection, pharmaceuticals and personal care. Balchem’s portfolio is built around core technologies such as advanced chelation, microencapsulation and custom ultrafine powders. The company’s Specialty Products segment offers chelated minerals and microencapsulation solutions designed to improve nutrient delivery, stability and shelf life. Its Human Nutrition & Health segment provides ingredients and application expertise for dietary supplements, medical foods and functional beverages. Balchem’s proprietary technologies are applied to enhance flavor, protect sensitive materials and ensure precise dosage in both food and pharmaceutical formulations. Founded in 1967 as Baltimore Chemical Company, Balchem adopted its current name in 2010 to reflect its expanded global scope and product offerings. Headquartered in New Hampton, New York, the company operates manufacturing and research facilities across North America, Europe and Asia. Balchem’s global footprint enables it to serve multinational customers and comply with regional regulatory requirements. Under the leadership of President and Chief Executive Officer Thomas F. Coughlin, Balchem emphasizes innovation, quality and sustainability. The company invests in ongoing research and development to address emerging nutritional trends and regulatory challenges, positioning itself as a partner for customers seeking advanced ingredient solutions worldwide.AI Generated. May Contain Errors. Read More Balchem Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreBCPC MarketRank™: Balchem scored higher than 49% of companies evaluated by MarketBeat, and ranked 116th out of 181 stocks in the basic materials sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingBuy Consensus RatingBalchem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and no sell ratings.Upside/DownsideThe consensus price target for Balchem is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageBalchem has only been the subject of 1 research reports in the past 90 days.Read more about Balchem's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth5.26% Earnings GrowthEarnings for Balchem are expected to grow by 5.26% in the coming year, from $5.70 to $6.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Balchem is 33.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Balchem is 33.21, which means that it is trading at a more expensive P/E ratio than the Basic Materials sector average P/E ratio of about 22.99.Price to Earnings Growth RatioBalchem has a PEG Ratio of 3.15. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBalchem has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Balchem's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.09% of the float of Balchem has been sold short.Short Interest Ratio / Days to CoverBalchem has a short interest ratio ("days to cover") of 1.35, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Balchem has recently increased by 0.52%, indicating that investor sentiment is decreasing. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldBalchem has a dividend yield of 0.59%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthBalchem has been increasing its dividend for 16 years.Dividend CoverageThe dividend payout ratio of Balchem is 19.71%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Balchem will have a dividend payout ratio of 16.00% next year. This indicates that Balchem will be able to sustain or increase its dividend.Read more about Balchem's dividend. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Balchem this week, compared to 3 articles on an average week.Search Interest1 people have searched for BCPC on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Balchem insiders have not sold or bought any company stock.Percentage Held by Insiders1.39% of the stock of Balchem is held by insiders.Percentage Held by Institutions87.91% of the stock of Balchem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Balchem's insider trading history. Receive BCPC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Balchem and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCPC Stock News HeadlinesAre options traders betting on a big move in Balchem stock?May 20, 2026 | msn.comShould Balchem’s Q1 2026 Earnings Jump and Buyback Activity Require Action From Balchem (BCPC) Investors?May 14, 2026 | finance.yahoo.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.May 24 at 1:00 AM | Behind the Markets (Ad)Balchem Corporation (NASDAQ:BCPC) Q1 2026 Earnings Call TranscriptMay 4, 2026 | insidermonkey.comBalchem: Buy Rating Reiterated as Earnings Outlook Improves and $190 Price Target Is MaintainedMay 4, 2026 | tipranks.comBalchem signals continued year-over-year growth amid petrochemical inflation riskApril 30, 2026 | seekingalpha.comBalchem (BCPC) Q1 2026 Earnings TranscriptApril 30, 2026 | finance.yahoo.comBalchem Earnings Call Highlights Record Growth, ResilienceApril 30, 2026 | tipranks.comSee More Headlines BCPC Stock Analysis - Frequently Asked Questions How have BCPC shares performed this year? Balchem's stock was trading at $153.36 at the beginning of 2026. Since then, BCPC shares have increased by 5.5% and is now trading at $161.75. How were Balchem's earnings last quarter? Balchem Corporation (NASDAQ:BCPC) posted its quarterly earnings data on Thursday, April, 30th. The basic materials company reported $1.33 earnings per share for the quarter, missing the consensus estimate of $1.41 by $0.08. The basic materials company earned $270.71 million during the quarter, compared to analyst estimates of $266.50 million. Balchem had a net margin of 14.95% and a trailing twelve-month return on equity of 13.38%. Read the conference call transcript. Does Balchem have any subsidiaries? The following companies are subsidiaries of Balchem: Zumbro River Brand Inc., Chemogas Holding NV, Bioscreen technologies, Innovative Food Processors, Chol-Mix Kft, Albion Laboratories Inc., SensoryEffects, and others. Who are Balchem's major shareholders? Balchem's top institutional investors include Wasatch Advisors LP (4.44%), Conestoga Capital Advisors LLC (3.91%), Dimensional Fund Advisors LP (1.86%) and First Trust Advisors LP (1.41%). Insiders that own company stock include Theodore L Harris, Gunsteren Job Leonard Van, David B Fischer, William A Backus and Michael Robert Sestrick. View institutional ownership trends. How do I buy shares of Balchem? Shares of BCPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Balchem own? Based on aggregate information from My MarketBeat watchlists, some other companies that Balchem investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings4/30/2026Today5/24/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 3 weeks, BCPC's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorBasic Materials Industry CHEM - SPECIALTY Sub-IndustrySpecialty Chemicals Current SymbolNASDAQ:BCPC Previous SymbolNASDAQ:BCPC CIK9326 Webwww.balchem.com Phone(845) 326-5600Fax845-326-5717Employees1,352Year Founded1967Price Target and Rating Average Price Target for Balchem$176.00 High Price Target$190.00 Low Price Target$162.00 Potential Upside/Downside+8.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$4.87 Trailing P/E Ratio33.21 Forward P/E Ratio28.38 P/E Growth3.15Net Income$154.85 million Net Margins14.95% Pretax Margin19.26% Return on Equity13.38% Return on Assets10.17% Debt Debt-to-Equity Ratio0.15 Current Ratio2.55 Quick Ratio1.59 Sales & Book Value Annual Sales$1.04 billion Price / Sales5.01 Cash Flow$6.59 per share Price / Cash Flow24.53 Book Value$40.00 per share Price / Book4.04Miscellaneous Outstanding Shares32,130,000Free Float31,683,000Market Cap$5.20 billion OptionableOptionable Beta0.85 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:BCPC) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Balchem Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Balchem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
